AAPL333.08+0.81 (+0.24%) ▲|ABBV261.77+4.65 (+1.81%) ▲|ABT103.09+1.14 (+1.12%) ▲|ACN195.00+11.10 (+6.04%) ▲|ADBE265.60+13.37 (+5.30%) ▲|AMAT424.21-32.28 (-7.07%) ▼|AMD493.41-22.72 (-4.40%) ▼|AMGN381.50+4.15 (+1.10%) ▲|AMT176.94-0.91 (-0.51%) ▼|AMZN253.54-3.24 (-1.26%) ▼|AVGO344.72-17.27 (-4.77%) ▼|AXP327.78+3.09 (+0.95%) ▲|BA210.27-0.18 (-0.09%) ▼|BAC59.47-3.22 (-5.14%) ▼|BKNG175.35+1.43 (+0.82%) ▲|BLK1,065.60-14.05 (-1.30%) ▼|BMY64.10+0.46 (+0.72%) ▲|BNY157.66-5.00 (-3.07%) ▼|BRK-B514.95+4.58 (+0.90%) ▲|C136.18-2.64 (-1.90%) ▼|CAT784.00-34.57 (-4.22%) ▼|CL87.89+1.09 (+1.26%) ▲|CMCSA24.88-0.32 (-1.27%) ▼|COF206.68-1.62 (-0.78%) ▼|COP136.67-0.68 (-0.50%) ▼|COST918.91+14.14 (+1.56%) ▲|CRM259.43+11.71 (+4.73%) ▲|CSCO110.06-2.07 (-1.85%) ▼|CVS95.55+0.89 (+0.94%) ▲|CVX212.17-1.89 (-0.88%) ▼|DE681.46+5.72 (+0.85%) ▲|DHR203.25+3.11 (+1.55%) ▲|DIS108.59+2.04 (+1.91%) ▲|DUK119.02-0.40 (-0.34%) ▼|EMR148.30-3.89 (-2.56%) ▼|FDX312.57+1.80 (+0.58%) ▲|GD356.81+0.91 (+0.26%) ▲|GE317.56-6.10 (-1.88%) ▼|GEV874.76-82.51 (-8.62%) ▼|GILD146.41+2.69 (+1.87%) ▲|GM87.16+1.54 (+1.80%) ▲|GOOG345.71+10.26 (+3.06%) ▲|GOOGL349.39+10.89 (+3.22%) ▲|GS988.45-40.73 (-3.96%) ▼|HD310.87+2.13 (+0.69%) ▲|HON201.38-0.98 (-0.48%) ▼|IBM249.09+5.80 (+2.38%) ▲|INTC97.19-5.75 (-5.59%) ▼|INTU339.15+17.58 (+5.47%) ▲|ISRG377.94+8.79 (+2.38%) ▲|JNJ266.32+0.74 (+0.28%) ▲|JPM350.13-6.10 (-1.71%) ▼|KO89.35+1.06 (+1.20%) ▲|LIN464.41-1.81 (-0.39%) ▼|LLY1,138.28+22.58 (+2.02%) ▲|LMT529.38+5.19 (+0.99%) ▲|LOW198.17+1.35 (+0.69%) ▲|LRCX273.49-24.73 (-8.29%) ▼|MA574.42+5.23 (+0.92%) ▲|MCD257.49+4.96 (+1.96%) ▲|MDLZ62.39-0.05 (-0.08%) ▼|MDT93.80+2.84 (+3.12%) ▲|META665.60+17.57 (+2.71%) ▲|MMM162.02-2.95 (-1.79%) ▼|MO70.61+1.63 (+2.36%) ▲|MRK144.85+0.92 (+0.64%) ▲|MS206.58-7.80 (-3.64%) ▼|MSFT505.41+9.78 (+1.97%) ▲|MU924.03-51.23 (-5.25%) ▼|NEE81.63-0.68 (-0.83%) ▼|NFLX80.32+2.92 (+3.77%) ▲|NKE37.05+0.25 (+0.68%) ▲|NOW142.35+9.82 (+7.41%) ▲|NVDA210.96-7.33 (-3.36%) ▼|ORCL144.79-5.49 (-3.65%) ▼|PEP136.34+0.02 (+0.01%) ▲|PFE27.72+0.00 (+0.00%) ▲|PG146.13+0.86 (+0.59%) ▲|PLTR173.31+6.08 (+3.64%) ▲|PM194.86+3.80 (+1.99%) ▲|QCOM180.15-1.82 (-1.00%) ▼|RTX195.34-2.34 (-1.18%) ▼|SBUX99.07+0.33 (+0.33%) ▲|SCHW107.31+0.06 (+0.06%) ▲|SO87.00-0.17 (-0.20%) ▼|SPG204.97+0.14 (+0.07%) ▲|T26.51+0.45 (+1.73%) ▲|TMO613.62+3.80 (+0.62%) ▲|TMUS182.90+0.57 (+0.31%) ▲|TSLA358.97-6.47 (-1.77%) ▼|TXN263.42-5.28 (-1.97%) ▼|UBER72.63+0.96 (+1.34%) ▲|UNH383.55+6.78 (+1.80%) ▲|UNP285.08+0.68 (+0.24%) ▲|UPS102.46+2.18 (+2.17%) ▲|USB62.68-0.16 (-0.25%) ▼|V375.28+4.83 (+1.30%) ▲|VZ51.29+0.68 (+1.34%) ▲|WFC88.71-1.58 (-1.75%) ▼|WMT109.08+1.93 (+1.80%) ▲|XOM165.08-0.91 (-0.55%) ▼|AAPL333.08+0.81 (+0.24%) ▲|ABBV261.77+4.65 (+1.81%) ▲|ABT103.09+1.14 (+1.12%) ▲|ACN195.00+11.10 (+6.04%) ▲|ADBE265.60+13.37 (+5.30%) ▲|AMAT424.21-32.28 (-7.07%) ▼|AMD493.41-22.72 (-4.40%) ▼|AMGN381.50+4.15 (+1.10%) ▲|AMT176.94-0.91 (-0.51%) ▼|AMZN253.54-3.24 (-1.26%) ▼|AVGO344.72-17.27 (-4.77%) ▼|AXP327.78+3.09 (+0.95%) ▲|BA210.27-0.18 (-0.09%) ▼|BAC59.47-3.22 (-5.14%) ▼|BKNG175.35+1.43 (+0.82%) ▲|BLK1,065.60-14.05 (-1.30%) ▼|BMY64.10+0.46 (+0.72%) ▲|BNY157.66-5.00 (-3.07%) ▼|BRK-B514.95+4.58 (+0.90%) ▲|C136.18-2.64 (-1.90%) ▼|CAT784.00-34.57 (-4.22%) ▼|CL87.89+1.09 (+1.26%) ▲|CMCSA24.88-0.32 (-1.27%) ▼|COF206.68-1.62 (-0.78%) ▼|COP136.67-0.68 (-0.50%) ▼|COST918.91+14.14 (+1.56%) ▲|CRM259.43+11.71 (+4.73%) ▲|CSCO110.06-2.07 (-1.85%) ▼|CVS95.55+0.89 (+0.94%) ▲|CVX212.17-1.89 (-0.88%) ▼|DE681.46+5.72 (+0.85%) ▲|DHR203.25+3.11 (+1.55%) ▲|DIS108.59+2.04 (+1.91%) ▲|DUK119.02-0.40 (-0.34%) ▼|EMR148.30-3.89 (-2.56%) ▼|FDX312.57+1.80 (+0.58%) ▲|GD356.81+0.91 (+0.26%) ▲|GE317.56-6.10 (-1.88%) ▼|GEV874.76-82.51 (-8.62%) ▼|GILD146.41+2.69 (+1.87%) ▲|GM87.16+1.54 (+1.80%) ▲|GOOG345.71+10.26 (+3.06%) ▲|GOOGL349.39+10.89 (+3.22%) ▲|GS988.45-40.73 (-3.96%) ▼|HD310.87+2.13 (+0.69%) ▲|HON201.38-0.98 (-0.48%) ▼|IBM249.09+5.80 (+2.38%) ▲|INTC97.19-5.75 (-5.59%) ▼|INTU339.15+17.58 (+5.47%) ▲|ISRG377.94+8.79 (+2.38%) ▲|JNJ266.32+0.74 (+0.28%) ▲|JPM350.13-6.10 (-1.71%) ▼|KO89.35+1.06 (+1.20%) ▲|LIN464.41-1.81 (-0.39%) ▼|LLY1,138.28+22.58 (+2.02%) ▲|LMT529.38+5.19 (+0.99%) ▲|LOW198.17+1.35 (+0.69%) ▲|LRCX273.49-24.73 (-8.29%) ▼|MA574.42+5.23 (+0.92%) ▲|MCD257.49+4.96 (+1.96%) ▲|MDLZ62.39-0.05 (-0.08%) ▼|MDT93.80+2.84 (+3.12%) ▲|META665.60+17.57 (+2.71%) ▲|MMM162.02-2.95 (-1.79%) ▼|MO70.61+1.63 (+2.36%) ▲|MRK144.85+0.92 (+0.64%) ▲|MS206.58-7.80 (-3.64%) ▼|MSFT505.41+9.78 (+1.97%) ▲|MU924.03-51.23 (-5.25%) ▼|NEE81.63-0.68 (-0.83%) ▼|NFLX80.32+2.92 (+3.77%) ▲|NKE37.05+0.25 (+0.68%) ▲|NOW142.35+9.82 (+7.41%) ▲|NVDA210.96-7.33 (-3.36%) ▼|ORCL144.79-5.49 (-3.65%) ▼|PEP136.34+0.02 (+0.01%) ▲|PFE27.72+0.00 (+0.00%) ▲|PG146.13+0.86 (+0.59%) ▲|PLTR173.31+6.08 (+3.64%) ▲|PM194.86+3.80 (+1.99%) ▲|QCOM180.15-1.82 (-1.00%) ▼|RTX195.34-2.34 (-1.18%) ▼|SBUX99.07+0.33 (+0.33%) ▲|SCHW107.31+0.06 (+0.06%) ▲|SO87.00-0.17 (-0.20%) ▼|SPG204.97+0.14 (+0.07%) ▲|T26.51+0.45 (+1.73%) ▲|TMO613.62+3.80 (+0.62%) ▲|TMUS182.90+0.57 (+0.31%) ▲|TSLA358.97-6.47 (-1.77%) ▼|TXN263.42-5.28 (-1.97%) ▼|UBER72.63+0.96 (+1.34%) ▲|UNH383.55+6.78 (+1.80%) ▲|UNP285.08+0.68 (+0.24%) ▲|UPS102.46+2.18 (+2.17%) ▲|USB62.68-0.16 (-0.25%) ▼|V375.28+4.83 (+1.30%) ▲|VZ51.29+0.68 (+1.34%) ▲|WFC88.71-1.58 (-1.75%) ▼|WMT109.08+1.93 (+1.80%) ▲|XOM165.08-0.91 (-0.55%) ▼|
20.9 C
New York
Tuesday, September 15, 2026

Tag: form

T1 Energy Strategy Supported by Section 232 Polysilicon and AD/CVD Investigations

T1 Energy Strategy Supported by Section 232 Polysilicon and AD/CVD Investigations. T1's contract for U.S. made polysilicon is a competitive advantage.

Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C

CELEBRATION, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare diseases, announced the company submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the evaluation of arimoclomol for the treatment of Niemann-Pick Disease Type C (NPC). NPC is an ultra-rare, neurological disease caused by genetic mutations that result in lipid accumulation in cells, leading to visceral, neurological, and psychiatric symptoms. Arimoclomol is the only treatment shown to directly target the underlying pathology of NPC by increasing gene expression for improved lipid clearance. Arimoclomol for the treatment of NPC has been designated as an Orphan Medicinal Product by the EMA. Arimoclomol is marketed in the U.S. under the brand name MIPLYFFA®.

Ardagh Metal Packaging S.A.’s Parent Company, Ardagh Group S.A., Announces Comprehensive Recapitalization Transaction

LUXEMBOURG, July 28, 2025 /PRNewswire/ -- On March 11, 2025 and as further updated on April 7, 2025 and May 20, 2025, Ardagh Group...

Consortium Led by Nordic Capital and Permira Will Make All-Cash Recommended Purchase Offer for Bavarian Nordic

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

Konsortium ledet af Nordic Capital og Permira vil fremsætte kontant frivilligt anbefalet købstilbud vedrørende Bavarian Nordic

MÅ IKKE UDGIVES, OFFENTLIGGØRES ELLER DISTRIBUERES, DIREKTE ELLER INDIREKTE, I ELLER TIL NOGEN JURISDIKTION, HVOR DETTE VILLE UDGØRE EN OVERTRÆDELSE AF DE RELEVANTE LOVE ELLER FORORDNINGER I DEN PÅGÆLDENDE JURISDIKTION

IRIS INSURANCE BROKERS LAUNCHES DEDICATED RESIDUAL VALUE INSURANCE CENTRE OF EXCELLENCE

LONDON, July 28, 2025 /PRNewswire/ -- Iris Insurance Brokers, a specialist Lloyd's Broker headquartered in London, has announced the launch of a dedicated Residual...

Roche presents new insights in Alzheimer’s disease research across its diagnostics and pharmaceutical portfolios at AAIC

Basel, 28 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its Alzheimer’s development portfolio is being presented at the Alzheimer’s Association International Conference (AAIC) in Toronto, Canada (July 27-30). These data exemplify the comprehensive approach Roche is taking in addressing Alzheimer’s across the entire patient journey. 

Windfall Mining Group inc. reaches a new milestone in its development in Quebec

MONTREAL, July 27, 2025 /CNW/ - Windfall Mining Group inc. (WMG), Canadian subsidiary of the global gold group Gold Fields Limited, announces today a...

TOP RANKED ROSEN LAW FIRM Encourages Vera Bradley, Inc. Investors to Inquire About Securities Class Action Investigation – VRA

NEW YORK, July 27, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Vera Bradley, Inc. (NASDAQ: VRA) resulting from allegations that Vera Bradley may have issued materially misleading business information to the investing public.

רוזן, משרד עורכי דין אמין ומוביל, מעודד את משקיעי Biohaven Ltd להשיג ייעוץ לפני מועד חשוב בתביעה ייצוגית בניירות ערך – BHVN

ניו יורק, July 27, 2025 (GLOBE NEWSWIRE) --

מדוע: משרד רוזן עורכי דין (Rosen Law Firm), משרד עורכי דין בינלאומי העוסק בזכויות משקיעים, מזכיר לרוכשים את ניירות הערך של  Biohaven Ltd. (NYSE: BHVN) בין התאריכים 24 במרץ 2023 עד 14 במאי 2025, שני התאריכים כוללים ("התקופה הייצוגית"), את המועד האחרון החשוב של 12 בספטמבר 2025 להגשת תביעה ייצוגית בניירות ערך.

SLP Investor News: If You Have Suffered Losses in Simulations Plus, Inc. (NASDAQ: SLP), You Are Encouraged to Contact The Rosen Law Firm About...

NEW YORK, July 26, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from allegations that Simulations Plus may have issued materially misleading business information to the investing public.

Bitcoin Swift Nears Completion of Stage 1 Presale with $1 Token Price and AI-Powered Rewards System

LUXEMBOURG, July 26, 2025 (GLOBE NEWSWIRE) -- Bitcoin Swift (BTC3), a next-generation blockchain infrastructure protocol, is approaching the final hours of Stage 1 of its presale, offering early adopters programmable Proof-of-Yield (PoY) rewards and ecosystem access at a fixed entry price of $1.00. The project has drawn attention for launching with built-in staking incentives, AI-driven governance, and a collateral-backed stablecoin—all live from day one.

Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop

– Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel long-acting herpes simplex virus helicase-primase inhibitor candidates –

ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED FIRM, Encourages Easterly ROCMuni High Income Municipal Bond Fund f/k/a Principal Street High Income Municipal Fund Investors...

NEW YORK, July 25, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of shares of the Easterly ROCMuni High Income Municipal Bond Fund f/k/a Principal Street High Income Municipal Fund (the “Fund”) (tickers: RMJAX, RMHVX, RMHIX), between May 5, 2023 and June 12, 2025, inclusive (the “Class Period”). The Fund is a mutual fund within defendant James Alpha Funds Trust’s series of mutual funds (which does business as Easterly Funds Trust). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 22, 2025.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsForm